● Leidos reported record second-quarter 2026Revenueof about $4.56 billion, up 7% year over year, and raised its full-year 2026 guidance.
● Bolt Biotherapeutics reported a second-quarter 2026 net loss of about $7.7 million and held about $18.1 million in cash, expected to fund operations into early 2027.
● Salesforce reported fiscal second-quarter 2027 totalRevenueof about $11.3 billion, up 11% year over year, with subscription and support revenue up 12%.
● Deckers reported record fiscal first-quarter 2027 net sales of about $1.020 billion, up 5.7% year over year, with HOKA up 7.7% and UGG up 4.9%.
● Digimarc reported second-quarter 2026Revenueof about $7.4 million, down roughly 7% year over year, with annualRecurring Revenuealso declining.
● Driven Brands reported second-quarter 2026Revenueof about $507.4 million, up about 7% year over year, withNet Incomeof about $37.3 million.
● Accenture reported fiscal third-quarter 2026Revenueof about $18.7 billion, up 6% in U.S. dollars, withGAAPdiluted EPS of $3.80, up 9%.
● Aptevo reported a clinical benefit rate of about 87% and a remission rate of about 81% in its RAINIER trial of mipletamig for frontline AML.
● HeartBeam received FDA clearance for its cable-free, synthesized 12-lead ECG technology and is moving toward a U.S. commercial launch.
● Badger Meter reported second-quarter 2026Revenueof about $222.3 million, topping estimates with sequential gains.